NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ANDRODERM (testosterone) by AbbVie is androgen receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANDRODERM is a transdermal testosterone replacement therapy approved in 1995 for hormone deficiency in men. It delivers testosterone through an extended-release film applied to the skin, mimicking natural androgen production. The drug works by activating androgen receptors to restore normal testosterone levels.
$0.003BPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with modest Part D spend ($3M) and low claim volume (4K); brand team likely focused on managed decline and market share defense against generics.
Mechanism of Action
Androgen Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
20 enrolled
Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Started Jul 2025
48 enrolled
Spinal Cord InjuriesEndothelial DysfunctionTestosterone Deficiency
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Started Mar 2025
100 enrolled
Hypogonadism, Male
Puberty, Testosterone, and Brain Development
Started Dec 2024
100 enrolled
Gender IdentityGender Dysphoria in Adolescents and AdultsHeadache+1 more
Worked on ANDRODERM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.